ASCO 2024 | Evaluating the safety of SX-682, a CXCR1/2 inhibitor, with pembrolizumab in melanoma
Sapna Patel, BA, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the safety findings in the Phase I trial (NCT03161431) of SX-682, a CXCR1/2 inhibitor, with pembrolizumab in patients with metastatic melanoma. Patients receiving SX-682 monotherapy had no dose-limiting toxicities but patients receiving 200mg SX-682 twice a day and subsequent pembrolizumab reported adverse events related to the checkpoint inhibitor. However, direct combination therapy did not result in dose-limiting toxicities. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria – Emory University
Consulting or Advisory Role – Bristol Myers Squibb; Cardinal Health; Castle Biosciences; Delcath Systems; IDEAYA Biosciences; immatics; Immunocore; MSD; Novartis; OncoSec; Pfizer; Replimune; TriSalus Life Sciences
Speakers’ Bureau – BMS GmbH & Co. KG; MSD
Research Funding – Bristol-Myers Squibb (Inst); Foghorn Therapeutics (Inst); IDEAYA Biosciences (Inst); InxMed (Inst); Lyvgen Biopharma (Inst); Novartis (Inst); Provectus (Inst); Seagen (Inst); Syntrix Biosystems (Inst); TriSalus Life Sciences (Inst)
Travel, Accommodations, Expenses – BMS GmbH & Co. KG; Castle Biosciences; InxMed; TriSalus Life Sciences
